View Item 

Show simple item record

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

dc.contributor.authorFunk, M. L.en_US
dc.contributor.authorRosenberg, D. M.en_US
dc.contributor.authorLok, Anna Suk-Fongen_US
dc.date.accessioned2010-06-01T19:05:37Z
dc.date.available2010-06-01T19:05:37Z
dc.date.issued2002-01en_US
dc.identifier.citationFunk, M. L. ; Rosenberg, D. M. ; Lok, A. S. F. (2002). "World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants." Journal of Viral Hepatitis 9(1): 52-61. <http://hdl.handle.net/2027.42/72281>en_US
dc.identifier.issn1352-0504en_US
dc.identifier.issn1365-2893en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72281
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11851903&dopt=citationen_US
dc.format.extent157826 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rightsBlackwell Science Ltden_US
dc.subject.otherChronic Hepatitis Ben_US
dc.subject.otherCore Promoteren_US
dc.subject.otherEpidemiologyen_US
dc.subject.otherPrecoreen_US
dc.titleWorld-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variantsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USAen_US
dc.contributor.affiliationotherDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA,en_US
dc.contributor.affiliationotherWorldwide Epidemiology Department, GlaxoSmithKline, Research Triangle Park, USA,en_US
dc.contributor.affiliationotherGreenford, UK,en_US
dc.identifier.pmid11851903en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72281/1/j.1365-2893.2002.00304.x.pdf
dc.identifier.doi10.1046/j.1365-2893.2002.00304.xen_US
dc.identifier.sourceJournal of Viral Hepatitisen_US
dc.identifier.citedreference1 World Health Organization. Hepatitis B. Fact sheet. http://www.who.int/inf-fs/en/fact204.html, Accessed: 12 December 2000.en_US
dc.identifier.citedreferenceLok ASF. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10: 46 – 52.en_US
dc.identifier.citedreferenceFattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998; 45: 1206 – 1213.en_US
dc.identifier.citedreferenceParkin DM, Pisani P, MuÑoz N, Ferlay J. The global health burden of infection associated cancers. In: Newton R, Beral V, Weiss RA, eds. Infections and Human Cancer. Plainview, New York: Cold Spring Harbor Laboratory Press, 1999: 5–33.en_US
dc.identifier.citedreferenceHadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B. From clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995; 1: 7 – 36.en_US
dc.identifier.citedreferenceChan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763 – 768.en_US
dc.identifier.citedreferenceCarman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588 – 591.en_US
dc.identifier.citedreferenceBrunetto MR, Stemler M, Bonino F et al. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990; 10: 258 – 261.en_US
dc.identifier.citedreferenceMoriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996; 226: 269 – 280.en_US
dc.identifier.citedreferenceTakahashi K, Aoyama K, Ohno N et al. The precore/core promoter mutant (T 1762 A 1764 ) of hepatitis B virus: Clinical significance and an easy method for detection. J Gen Virol 1995; 76: 3159 – 3164.en_US
dc.identifier.citedreferenceBuckwold VE, Xu Z, Chen M, Yen TSB, Ou J-H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70: 5845 – 5851.en_US
dc.identifier.citedreferenceHoofnagle JH, Lok A, Heathcote J. Standardization of nomenclature for hepatitis B. In: Workshop on Management of Hepatitis B 2000. NIH, Bethesda, MD: National Institutes of Health, 2000.en_US
dc.identifier.citedreferenceLi J-S, Tong S-P, Wen Y-M, Vitvitski L, Zhang Q, TrÉpo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: Possible contribution of a single nucleotide in the precore region. J Virol 1993; 67: 5402 – 5410.en_US
dc.identifier.citedreferenceLindh M, Andersson A-S, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – Large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285 – 1293.en_US
dc.identifier.citedreferenceNorder H, Hammans B, Lee S-D et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol 1993; 74: 1341 – 1348.en_US
dc.identifier.citedreferenceArauz-Ruiz P, Norder H, VisonÁ KA, Magnius LO. Genotype F prevails in HBV infected patients of hispanic origin in Central America and may carry the precore stop mutant. J Med Virol 1997; 51: 305 – 312.en_US
dc.identifier.citedreferenceRizzetto M. Viral hepatitis in the third millennium. Res Virol 1998; 149: 251 – 256.en_US
dc.identifier.citedreferenceGiusti G, Galanti B, Gaeta GB, Sagnelli E, Piccinino F, Ruggiero G. Clinical presentation and natural history of chronic persistent hepatitis. A multicentre retrospective study on 1197 cases. Ital J Gastroenterol 1991; 23: 111 – 118.en_US
dc.identifier.citedreferenceMatsuyama Y, Omata M, Yokosuka O, Imazeki F, Ito Y, Okuda K. Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum. Gastroenterology 1985; 89: 1104 – 1108.en_US
dc.identifier.citedreferenceShindo M, Hamada K, Koya S, Sokawa Y, Okuno T. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94: 2237 – 2245.en_US
dc.identifier.citedreferenceOkamato H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102 – 8110.en_US
dc.identifier.citedreferenceTakahashi K, Ohta Y, Kanai K et al. Clinical implications of mutations C-to-T 1653 and T-to-C/A/G 1753 of hepatitis B virus genotype C genome in chronic liver disease. Arch Virol 1999; 144: 1299 – 1308.en_US
dc.identifier.citedreferenceLok ASF, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994; 91: 4077 – 4081.en_US
dc.identifier.citedreferenceStuyver L, De Gendt S, Van Geyt C et al. A new genotype of hepatitis B virus: complete genome and phylogenetic related- ness. J Gen Virol 2000; 81: 67 – 74.en_US
dc.identifier.citedreferenceRodriguez-Frias F, Buti M, Jardi R et al. Hepatitis B virus infection: Precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 1641 – 1647.en_US
dc.identifier.citedreferenceChan HLY, Hussain M, Lok ASF. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976 – 984.en_US
dc.identifier.citedreferenceBrunetto MR, Giarin M, Saracco G et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105: 845 – 850.en_US
dc.identifier.citedreferenceFattovich G, Farci P, Rugge M et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 584 – 589.en_US
dc.identifier.citedreferenceHadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; 11: S133 – S136.en_US
dc.identifier.citedreferencePastore G, Santantonio T, Milella M et al. Anti-HBe-positive chronic hepatitis B with HBV DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14: 221 – 225.en_US
dc.identifier.citedreferenceZhang X, Zoulim F, Habersetzer F, Xiong S, TrÉpo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48: 8 – 16.en_US
dc.identifier.citedreferenceLok ASF, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995; 21: 19 – 24.en_US
dc.identifier.citedreferenceErhardt A, Reineke U, Blondin D et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716 – 725.en_US
dc.identifier.citedreferenceHadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847 – 851.en_US
dc.identifier.citedreferenceSantantonio T, Mazzola M, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300 – 306.en_US
dc.identifier.citedreferenceTassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889 – 896.en_US
dc.identifier.citedreferenceTassopoulos NC, Volpes R, Pastore G et al. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J Hepatol 1999; 30 (suppl 1): 117 – 117 (abstr).en_US
dc.identifier.citedreferenceTassopoulos NC & Anagnostopoulos GD. Long-term lamivudine treatment of patients with precore mutant profile (HBeAg (−) /antiHBe (+)) chronic hepatitis B. Antiviral Ther 2000; 5 (suppl 1): 34 – 34 (abstract).en_US
dc.identifier.citedreferenceWong FS, Fung S, Lok ASF, Hussain M. Use of lamivudine in Chinese patients with hepatitis B e-antigen negative chronic hepatitis B. Hepatology 2000; 32: A864 – A864.en_US
dc.identifier.citedreferenceRizzetto M, Santantonio T, Buti M et al. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA-positive (pre-core mutant) chronic hepatitis B (CHB). Hepatology 2000; 32: A1197 – A1197.en_US
dc.identifier.citedreferenceLok ASF, Hussain M, Cursano C et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e-antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145 – 1153.en_US
dc.identifier.citedreferenceNakahori S, Yokosuka O, Ehata T et al. Detection of hepatitis B virus precore stop codon mutants by selective amplification method: Frequent detection of precore mutants in hepatitis B e antigen positive healthy carriers. J Gastroenterol Hepatol 1995; 10: 419 – 425.en_US
dc.identifier.citedreferenceNiitsuma H, Ishii M, Saito Y et al. Prevalence of precore-defective mutant of hepatitis B virus in HBV carriers. J Med Virol 1995; 46: 397 – 402.en_US
dc.identifier.citedreferenceIchikawa T, Takagi H, Kinoshita M, Shimoda R, Nagamine T, Mori M. Quantitative analysis of hepatitis B virus precore mutant in hepatitis type B. Tohoku J Exp Med 1998; 186: 323 – 333.en_US
dc.identifier.citedreferenceNagasaka A, Hige S, Marutani M et al. Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection. Dig Dis Sci 1998; 43: 2473 – 2478.en_US
dc.identifier.citedreferenceTian Q & Jia K. A kinetic study of hepatitis B virus pre-C gene mutation. Chung Hua Nei Ko Tsa Chih 1995; 34: 232 – 234.en_US
dc.identifier.citedreferenceTu H, Li PY, Wen YM. Anti-HBe titre in patients infected with wild-type and e-minus variant of hepatitis B virus. Res Virol 1996; 147: 39 – 43.en_US
dc.identifier.citedreferenceTu H, Xiong S-D, Trepo C, Wen Y-M. Frequency of hepatitis B virus e-minus mutants varies among patients from different areas of China. J Med Virol 1997; 51: 85 – 89.en_US
dc.identifier.citedreferenceHou J, Lau GKK, Cheng J, Cheng CC, Luo K, Carman WF. T 1762 /A 1764 variants of the basal core promoter of hepatitis B virus; serological and clinical correlations in Chinese patients. Liver 1999; 19: 411 – 417.en_US
dc.identifier.citedreferenceChu C-M, Karayiannis P, Fowler MJF, Monjardino J, Liaw Y-F, Thomas HC. Natural history of chronic hepatits B virus infection in Taiwan: Studies of hepatitis B virus DNA in serum. Hepatology 1985; 5: 431 – 434.en_US
dc.identifier.citedreferenceWu J-C, Lee S-D, Tsay S et al. Symptomatic anti-HBe positive chronic hepatitis B in Taiwan with special reference to persistent HBV replication and HDV superinfection. J Med Virol 1988; 25: 141 – 148.en_US
dc.identifier.citedreferenceLiaw Y-F, Sheen I-S, Chen T-J, Chu C-M, Pao C-C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991; 13: 627 – 631.en_US
dc.identifier.citedreferenceChu C-M, Yeh C-T, Chiu C-T, Sheen I-S, Liaw Y-F. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34: 1815 – 1818.en_US
dc.identifier.citedreferencePark YN, Han KH, Kim KS, Chung JP, Kim S, Park C. Cytoplasmic expression of hepatitis B core antigen in chronic hepatitis B virus infection: role of precore stop mutants. Liver 1999; 19: 199 – 205.en_US
dc.identifier.citedreferenceKim WH, Kim KH, Chung JP, Kang JK, Park IS. Mutations in the pre-core region of hepatitis B virus DNA in patients with chronic liver diseases. Yonsei Med J 1993; 34: 158 – 165.en_US
dc.identifier.citedreferenceSarin SK, Guptan RC, Banerjee K, Khandekar P. Low prevalence of hepatitis C viral infection in patients with non-alcoholic chronic liver disease in India. J Assoc Physicians India 1996; 44: 243 – 245.en_US
dc.identifier.citedreferenceGuptan RC, Thakur V, Sarin SK, Banerjee K, Khandekar P. Frequency and clinical profile of precore and surface hepatitis B mutants in Asian-Indian patients with chronic liver disease. Am J Gastroenterol 1996; 91: 1312 – 1317.en_US
dc.identifier.citedreferenceYap I, Wee A, Guan R. Chronic hepatitis B infection in Singapore. Singapore Med J 1991; 32: 352 – 355.en_US
dc.identifier.citedreferenceKidd-Ljunggren K, Ekdahl K, Öberg M, Kurathong S, Lolekha S. Hepatitis B virus strains in Thailand: Genomic variants in chronic carriers. J Med Virol 1995; 47: 454 – 461.en_US
dc.identifier.citedreferenceTon SH, Iskandar K, Noriah R, Thanaletchimy N. Nucleotide sequence of precore region of hepatitis B virus DNA in HBsAg-positive carriers in Malaysia. Scand J Infect Dis 1996; 28: 543 – 548.en_US
dc.identifier.citedreferenceRealdi G, Alberti A, Rugge M et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195 – 199.en_US
dc.identifier.citedreferenceNegro F, Chiaberge E, Oliviero S et al. Hepatitis B virus DNA (HBV-DNA) in anti-HBe positive sera. Liver 1984; 4: 177 – 183.en_US
dc.identifier.citedreferenceAlberti A, Pontisso P, Fattovich G et al. Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: Results of a long-term follow-up study of 138 patients. J Infect Dis 1986; 154: 562 – 569.en_US
dc.identifier.citedreferenceBonino F, Rosina F, Rizzetto M et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268 – 1273.en_US
dc.identifier.citedreferenceSantantonio T, Jung M, Miska S, Pastore G, Pape G, Will H. High prevalence and heterogeneity of HBV preC mutants in anti-HBe-positive carriers with chronic liver disease in Southern Italy. J Hepatol 1991; 13 (suppl 4): S78 – S81.en_US
dc.identifier.citedreferenceBrunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88: 4186 – 4190.en_US
dc.identifier.citedreferenceLai ME, Solinas A, Mazzoleni AP et al. The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. J Hepatol 1994; 20: 773 – 781.en_US
dc.identifier.citedreferenceHadziyannis S, Lieberman H, Karvountzis G, Shafritz D. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983; 3: 656 – 662.en_US
dc.identifier.citedreferenceLaras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 1998; 5: 241 – 248.en_US
dc.identifier.citedreferenceJardi R, Buti M, Rodriguez-Frias F et al. The value of quantitative detection of HBV-DNA amplified by PCR in the study of hepatitis B infection. J Hepatol 1996; 24: 680 – 685.en_US
dc.identifier.citedreferenceLÓpez-Alcorocho JM, Moraleda G, BartolomÉ J et al. Analysis of hepatitis B precore region in serum and liver of chronic hepatitis B virus carriers. J Hepatol 1994; 21: 353 – 360.en_US
dc.identifier.citedreferenceTur-Kaspa R, Keshet E, Eliakim M, Shouval D. Detection and characterization of hepatitits B virus DNA in serum of HBe antigen-negative HBsAg carriers. J Med Virol 1984; 14: 17 – 26.en_US
dc.identifier.citedreferenceTur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16: 1338 – 1342.en_US
dc.identifier.citedreferenceNaoumov NV, Schneider R, GrÖtzinger T et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102: 538 – 543.en_US
dc.identifier.citedreferenceBozdayi A, Bozkaya H, TÜrkyilmaz A et al. Polymorphism of precore region of hepatitis B virus DNA among patients with chronic HBV infection in Turkey. Infection 1999; 27: 357 – 360.en_US
dc.identifier.citedreferenceMangia A, Chung YH, Hoofnagle JH, Birkenmeyer L, Mushahwar I, Di Bisceglie AM. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. Dig Dis Sci 1996; 41: 2447 – 2452.en_US
dc.identifier.citedreferenceGray A, Fang J, Davis G et al. Variations of hepatitis B virus core gene sequence in Western patients with chronic hepatitis B virus infection. J Viral Hepat 1997; 4: 371 – 378.en_US
dc.identifier.citedreferenceTillmann H, Trautwein C, Walker D et al. Clinical relevance of mutations in the precore genome of the hepatitis B virus. Gut 1995; 37: 568 – 573.en_US
dc.identifier.citedreferenceKnÖll A, Rohrhofer A, Kochanowski B, Wurm EM, Jilg W. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J Med Virol 1999; 59: 14 – 18.en_US
dc.identifier.citedreferenceZarski J, Marcellin P, Cohard M, Lutz J, Bouche C, Rais A. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. J Hepatol 1994; 20: 636 – 640.en_US
dc.identifier.citedreferenceKidd Ljunggren K, Nordenfelt E, Kidd A. Correlation of HBeAg/Anti-HBe, ALT levels, and HBV DNA PCR results in HBsAg-positive patients. J Med Virol 1993; 39: 297 – 302.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2893.2002.00304.x.pdf
Size:
154.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.